Professor Esam Z. Dajani PhD, FACG

Professor Dajani provides litigation support and testimony in clinical pharmacology, toxicology, Cytotec, pharmaceutical patent litigations, drug injury, drug-related medical and pharmacy malpractice, drug product liability (e.g., warnings, designs, formulations, labelings), adverse effects of health and beauty products, alcohol and industrial chemicals, forensic aspects of alcohol/psychotropic drugs and Contract Research Organizations (CROs). He provides investigations, research, record analysis, consultations, merit statement and testimony.

Professor Dajani has >30 years experience in pre-clinical and clinical research and development. He directed worldwide clinical research at phar- maceutical companies. He led the research teams that discovered and developed misoprostol (Cytotec), an anti-ulcer drug. He is the founder and president of the International Drug Development Consultants Corporation (IDDC), a CRO.  He has some 260 biomedical publications, presentations, patents and book chapters. His research interests broadly include pharmacology, toxicology, drug safety, general medicine, prostaglandins, regulatory affairs (FDA), drug development, hormones, opiates, NSAIDs and complementary drugs. Since 1980, he held concurrent adjunct appointments in pharmacology  and medicine. Since 1995, he concurrently held Adjunct Professor of Medicine appointment at Loyola University-Chicago.